Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb;17(2):16.
doi: 10.1007/s11934-015-0567-x.

Silk Fibroin Scaffolds for Urologic Tissue Engineering

Bryan S Sack  1   2 , Joshua R Mauney  3   4   5 , Carlos R Estrada Jr  6   7   8
Affiliations
Review

Silk Fibroin Scaffolds for Urologic Tissue Engineering

Bryan S Sack et al. Curr Urol Rep. 2016 Feb.

Abstract

Urologic tissue engineering efforts have been largely focused on bladder and urethral defect repair. The current surgical gold standard for treatment of poorly compliant pathological bladders and severe urethral stricture disease is enterocystoplasty and onlay urethroplasty with autologous tissue, respectively. The complications associated with autologous tissue use and harvesting have led to efforts to develop tissue-engineered alternatives. Natural and synthetic materials have been used with varying degrees of success, but none has proved consistently reliable for urologic tissue defect repair in humans. Silk fibroin (SF) scaffolds have been tested in bladder and urethral repair because of their favorable biomechanical properties including structural strength, elasticity, biodegradability, and biocompatibility. SF scaffolds have been used in multiple animal models and have demonstrated robust regeneration of smooth muscle and urothelium. The pre-clinical data involving SF scaffolds in urologic defect repair are encouraging and suggest that they hold potential for future clinical use.

Keywords: Animal models; Bladder; Silk; Tissue engineering; Urethra; Urinary tract.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80–S87. - PMC - PubMed
    1. Edelstein RA, Bauer SB, Kelly MD, et al. The long-term urological response of neonates with myelodysplasia treated proactively with intermittent catheterization and anticholinergic therapy. J Urol. 1995;154(4):1500–1504. - PubMed
    1. Kaefer M, Pabby A, Kelly M, Darbey M, Bauer SB. Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele. J Urol. 1999;162(3 Pt 2):1068–1071. - PubMed
    1. Hensle TW, Gilbert SM. A review of metabolic consequences and long-term complications of enterocystoplasty in children. Curr Urol Rep. 2007;8(2):157–162. - PubMed
    1. Somani BK, Kumar V, Wong S, et al. Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. J Urol. 2007;177(5):1793–1798. - PubMed

Publication types